Skip to content

Multimodal Analgesia Versus Traditional Opiate Based Analgesia

Multimodal Analgesia Versus Traditional Opiate Based Analgesia and Cardiac Surgery Outcome

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03521167
Enrollment
225
Registered
2018-05-11
Start date
2018-05-01
Completion date
2019-12-30
Last updated
2018-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Surgery

Brief summary

Pain after cardiac surgery can be moderate to severe with incisions to the sternum and lower extremities, and also the placement of chest tubes. Postoperative pain may contribute to delirium, stress, myocardial oxygen demand supply imbalance, etc. Traditionally postoperative pain management after cardiac surgery has been based on opiate analgesics. However, opiates have many deleterious side effects including nausea/vomiting, ileus, bladder dysfunction, and respiratory depression, which substantially influence patient recovery and may delay discharge after surgery. The current study is designed to evaluate if an opiate sparing multimodal regimen of tylenol, gabapentin, ketamine, lidocaine and dexmedetomidine provided better analgesic effect (pain score, postoperative PCA opioid dose), less side effects (PONV) and improved cardiac surgery outcome (delirium, a-fib, AKI, dysglycemia) compared to a traditional fentanyl and hydromorphine regimen after cardiac surgery. Additionally, it aims to investigate if the benefit of multimodal regimen is achieved by combination of all drugs or all drugs except dexmedetomodine by introducing third group of study patients who will be randomized to all interventions except saline placebo instead of dexmedetomodine infusion.

Interventions

DRUGKetamine

Intraoperatively use. 0.5 mg/kg with induction bolus, followed by 5mcg/kg/min infusion after induction. Continue up to 1 hour prior to extubation. maximum total dose 3mg/kg.

DRUGLidocaine

Intraoperatively use. start lidocaine infusion at 2mg/min after anesthesia induction, and continue up to 1 hour prior to extubation.

DRUGDexmedetomidine

Intraoperatively use. start dexmedetomidine infusion at 0.5 mcg/kg/min after anesthesia induction, and continue up to 1 hour prior to extubation.

DRUGGabapentin

Postoperatively use. 300 mg PO TID starting POD1 until discharge Use lower dose for \>65y or if patient having significant sedation/dizziness

Postoperatively use. 1000 mg PO Q8hr starting POD0 until discharge (max 3000 mg in 24hrs) Reduce to 650 mg PO Q6h if \<70kg

Pre-operatively use. 300mg PO up to 1 hour before OR time Reduce to 100 mg PO in patients \>65y or with GFR \< 50 Consider dose reduction in patients with sleep apnea

Pre-operatively use. 1000 mg PO up to 1 hour before OR time Reduce to 650 mg PO if \<70kg Don't use if h/o liver disease or anticipated liver injury (right heart failure, pulmonary hypertension, etc leading to systemic venous congestion)

Sponsors

Shanghai Zhongshan Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* ASA II-III Grade * BMI 18-31kg/m2 * Adult patients presenting for on-pump cardiac surgery through median sternotomy

Exclusion criteria

* Cardiac surgery without sternotomy * emergency surgery * h/o allergy to any of the medications in the research protocol * hepatic disease with elevated liver enzymes (preoperative SGPT and SGOT elevated to 1.5 times maximum normal value) * pregnancy * unable to give consent * preoperative mental disorders

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of analgesic effectWithin 3 months after surgeryEvaluation of analgesic effect by Visual Analogue Scale

Secondary

MeasureTime frameDescription
Additional opioid consumptionWithin 3 days after operationassessed by daily sufentanil PCIA dose
postoperative deliriumWithin 3 days after operationevaluated by CAM-ICU criteria

Contacts

Primary ContactKefang Guo, PHD
drguokefang@foxmail.com+86-13817706936

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026